| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/jcisd/BaurinBRCFPJRPGMH04 |
| P356 | DOI | 10.1021/CI034260M |
| P698 | PubMed publication ID | 15032546 |
| P2093 | author name string | Baker R | |
| Jordan A | |||
| Richardson C | |||
| Morley D | |||
| Hubbard RE | |||
| Chen I | |||
| Potter A | |||
| Baurin N | |||
| Foloppe N | |||
| Greaney P | |||
| Parratt M | |||
| Roughley S | |||
| P2860 | cites work | SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules | Q28090714 |
| Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges | Q28096294 | ||
| Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties | Q28842810 | ||
| Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds | Q28842868 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 | ||
| Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces. | Q30643833 | ||
| Estimation of aqueous solubility of organic compounds with QSPR approach. | Q30733668 | ||
| Selection criteria for drug-like compounds | Q30901599 | ||
| Is there a difference between leads and drugs? A historical perspective | Q31017131 | ||
| Optimizing the size and configuration of combinatorial libraries | Q31136115 | ||
| Can We Learn To Distinguish between “Drug-like” and “Nondrug-like” Molecules? | Q32032942 | ||
| Estimation of aqueous solubility of chemical compounds using E-state indices | Q33843973 | ||
| Prediction of intestinal permeability | Q34581541 | ||
| Integration of virtual and high-throughput screening | Q34988235 | ||
| Current trends in lead discovery: are we looking for the appropriate properties? | Q35054077 | ||
| ADMET in silico modelling: towards prediction paradise? | Q35075770 | ||
| Experimental and computational screening models for the prediction of intestinal drug absorption | Q40802302 | ||
| Comparison of the NCI open database with seven large chemical structural databases. | Q42652302 | ||
| Prediction of aqueous solubility of organic compounds by the general solubility equation (GSE). | Q43768709 | ||
| Simultaneous prediction of aqueous solubility and octanol/water partition coefficient based on descriptors derived from molecular structure | Q43805832 | ||
| Modeling aqueous solubility | Q44454055 | ||
| Prediction of aqueous solubility and partition coefficient optimized by a genetic algorithm based descriptor selection method | Q47886757 | ||
| Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices | Q52067008 | ||
| Improving the odds in discriminating "drug-like" from "non drug-like" compounds | Q52069878 | ||
| Estimation of the aqueous solubility of organic molecules by the group contribution approach | Q52137482 | ||
| Prediction of Physicochemical Parameters by Atomic Contributions | Q56432347 | ||
| Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA | Q72741870 | ||
| Estimation of aqueous solubility for a diverse set of organic compounds based on molecular topology | Q73887710 | ||
| Absorption classification of oral drugs based on molecular surface properties | Q78896196 | ||
| Lead generation--enhancing the success of drug discovery by investing in the hit to lead process | Q78898367 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 643-651 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Journal of Chemical Information and Computer Sciences | Q104614957 |
| P1476 | title | Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds | |
| P478 | volume | 44 |
| Q30854803 | 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries |
| Q59406078 | A Chemometric Analysis of Compounds from Native New Zealand Medicinal Flora |
| Q91094627 | A Chemometric Analysis of Deep-Sea Natural Products |
| Q28546625 | A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress |
| Q28482507 | A chemocentric approach to the identification of cancer targets |
| Q33264565 | A cluster-based strategy for assessing the overlap between large chemical libraries and its application to a recent acquisition |
| Q49226937 | A perspective on multi-target drug discovery and design for complex diseases |
| Q91930920 | A perspective on the discovery of selected compounds with anthelmintic activity against the barber's pole worm-Where to from here? |
| Q45211014 | ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens |
| Q33244050 | An empirical process for the design of high-throughput screening deck filters. |
| Q42808123 | An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility |
| Q50641914 | Applicability domain based on ensemble learning in classification and regression analyses |
| Q84067874 | Are there differences between launched drugs, clinical candidates, and commercially available compounds? |
| Q33237551 | Assessing the scaffold diversity of screening libraries |
| Q59444508 | CHAPTER 8. Discovery of NVP-AUY922 |
| Q33382944 | CLEVER: pipeline for designing in silico chemical libraries. |
| Q57002001 | Capter 11 Filtering in Drug Discovery |
| Q45999839 | ChemMine. A compound mining database for chemical genomics. |
| Q35059291 | Cheminformatic analysis of high-throughput compound screens. |
| Q104493870 | Chemography: Searching for Hidden Treasures |
| Q83983839 | Chemometrics |
| Q80141780 | Collection and preparation of molecular databases for virtual screening |
| Q27656518 | Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone |
| Q56983467 | Computational Tools for ADMET Profiling |
| Q36724095 | Computational identification of inhibitors of protein-protein interactions. |
| Q26997089 | Computational methods in drug discovery |
| Q46890663 | Criterion for Evaluating the Predictive Ability of Nonlinear Regression Models without Cross-Validation |
| Q108527519 | Current Status of Virtual Combinatorial Library Design |
| Q31130642 | Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. |
| Q33730340 | Design of Screening Collections for Successful Fragment-Based Lead Discovery |
| Q81785248 | Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor |
| Q47866570 | Development of a new regression analysis method using independent component analysis |
| Q38795153 | Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening |
| Q34726028 | Discovery of a novel class of selective human CB1 inverse agonists |
| Q27645909 | Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping |
| Q36569418 | Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein. |
| Q47133447 | Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain |
| Q34776186 | Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening |
| Q33232965 | Diversity in medicinal chemistry space |
| Q83363936 | Drug- and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers |
| Q35198757 | Drug-like properties: guiding principles for design - or chemical prejudice? |
| Q34349819 | Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. |
| Q91068470 | Energy windows for computed compound conformers: covering artefacts or truly large reorganization energies? |
| Q58613946 | Evolution of commercially available compounds for HTS |
| Q33768454 | Experimental validation of a fragment library for lead discovery using SPR biosensor technology |
| Q42553799 | FAF-Drugs: free ADME/tox filtering of compound collections. |
| Q37799641 | False positives in the early stages of drug discovery |
| Q36477457 | Finding protein kinase hits using structural information |
| Q51935607 | FlexNovo: structure-based searching in large fragment spaces |
| Q33329074 | Fragment approaches in structure-based drug discovery |
| Q86491016 | Fragment library design: efficiently hunting drugs in chemical space |
| Q59444507 | Fragment-Based Lead Discovery |
| Q38184631 | Fragment-based lead discovery and design |
| Q37418578 | Fragment-based ligand discovery |
| Q34662757 | Free resources to assist structure-based virtual ligand screening experiments |
| Q57009154 | From Structure Diagrams to Visual Chemical Patterns |
| Q33925459 | Hsp90 inhibitors and drugs from fragment and virtual screening. |
| Q53600633 | Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening |
| Q35902399 | Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer |
| Q80257547 | Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches |
| Q43226248 | Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents |
| Q48519068 | Improving conformational searches by geometric screening. |
| Q36755747 | In silico design of protein kinase inhibitors: successes and failures. |
| Q38010517 | In silico prediction of cytochrome P450-mediated site of metabolism (SOM). |
| Q37130829 | In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics |
| Q38080968 | Interactive design of generic chemical patterns |
| Q33359104 | Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds |
| Q33215051 | Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection |
| Q36665679 | Knowledge-based chemoinformatic approaches to drug discovery |
| Q57748028 | Lead Identification by Virtual Screening |
| Q33259933 | Leadlikeness and structural diversity of synthetic screening libraries |
| Q33309109 | Lessons learnt from assembling screening libraries for drug discovery for neglected diseases |
| Q34060902 | Library enhancement through the wisdom of crowds |
| Q57176765 | Lignans: A Chemometric Analysis |
| Q33259936 | Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers |
| Q28298611 | Navigating chemical space for biology and medicine |
| Q30887386 | Optimizing the performance of in silico ADMET general models according to local requirements: MARS approach. solubility estimations as case study. |
| Q38453607 | PharmaTrek: A Semantic Web Explorer for Open Innovation in Multitarget Drug Discovery |
| Q96023635 | Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors |
| Q57008200 | Properties Guiding Drug- and Lead-Likeness |
| Q33546047 | QSAR in the pharmaceutical research setting: QSAR models for broad, large problems |
| Q28303907 | Rational methods for the selection of diverse screening compounds |
| Q33232966 | Recent developments in focused library design: targeting gene-families |
| Q33262082 | Receptor-based computational screening of compound databases: the main docking-scoring engines |
| Q51931319 | Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset |
| Q58581975 | Screening Library Design |
| Q46563176 | Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity |
| Q46734040 | Structure-based discovery of a new class of Hsp90 inhibitors |
| Q36749406 | SuperPred: drug classification and target prediction |
| Q51626371 | SwiFT: an index structure for reduced graph descriptors in virtual screening and clustering |
| Q33304857 | The SeeDs approach: integrating fragments into drug discovery |
| Q33651965 | The T1R2/T1R3 sweet receptor and TRPM5 ion channel taste targets with therapeutic potential |
| Q39870054 | The identification of novel PLC-gamma inhibitors using virtual high throughput screening |
| Q30354509 | Therapeutic targets: progress of their exploration and investigation of their characteristics. |
| Q31106801 | Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation |
| Q46563192 | Unveiling the full potential of flexible receptor docking using multiple crystallographic structures |
| Q31112340 | Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock |
| Q33247681 | Virtual ligand screening: strategies, perspectives and limitations |
| Q81727390 | Virtual screening using PLS discriminant analysis and ROC curve approach: an application study on PDE4 inhibitors |
| Q33962362 | Visual Characterization and Diversity Quantification of Chemical Libraries: 1. Creation of Delimited Reference Chemical Subspaces |
| Q36091191 | Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study |
| Q130188011 | k-nearest neighbor normalized error for visualization and reconstruction – A new measure for data visualization performance |
Search more.